The role of CD34+ cell proliferation, apoptosis and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS.

被引：0
|
作者：
Parker, JE [1 ]
Fishlock, KL [1 ]
Czepulkowski, B [1 ]
Pagliuca, A [1 ]
Mufti, GJ [1 ]
机构：
[1] Univ London Kings Coll, Sch Med & Dent, London WC2R 2LS, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1999年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
163
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [1] The role of apoptosis, proliferation and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS.
    Parker, JE
    Fishlock, KL
    Pagliuca, A
    Mufti, GJ
    BLOOD, 1998, 92 (10) : 418A - 419A
  • [2] Circulating CD34+ cells in the myelodysplastic syndromes (MDS).
    Cairoli, R
    Pezzetti, L
    Intropido, L
    Brando, B
    Santoleri, L
    Nosari, A
    Perego, RA
    Morra, E
    BLOOD, 1995, 86 (10) : 3152 - 3152
  • [3] Contrasting incidence of apoptosis in CD34+ vs. CD34- cells in myelodysplastic syndromes (MDS).
    Mundle, S
    Venugopal, P
    Shetty, V
    Ali, A
    Handa, H
    Rose, S
    Chopra, H
    Gregory, SA
    Preisler, H
    Raza, A
    BLOOD, 1997, 90 (10) : 2588 - 2588
  • [4] The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS
    Parker, JE
    Mufti, GJ
    Rasool, F
    Mijovic, A
    Devereux, S
    Pagliuca, A
    BLOOD, 2000, 96 (12) : 3932 - 3938
  • [5] Fas (CD95) expression in normal progenitor cells, myelodysplastic syndromes (MDS) and secondary AML (sAML).
    Kliche, KO
    Andreeff, M
    BLOOD, 1997, 90 (10) : 4043 - 4043
  • [6] CD34+ cells have a lower in vivo labeling index (LI) than CD34 negative cells in myelodysplastic syndromes (MDS).
    Span, L
    Shetty, V
    BroadyRobinson, L
    Mundle, SD
    Alvi, S
    Borok, R
    Reza, S
    Dar, S
    Boukhris, T
    Kumar, R
    Venugopal, P
    Gezer, S
    Robin, E
    Rifkin, S
    Hines, C
    Raza, A
    BLOOD, 1996, 88 (10) : 365 - 365
  • [7] Erythropoiesis is highly stimulated in CD34+ cells in low-risk myelodysplastic syndromes (MDS) with an improper mitochondrial function
    Tehranchi, R
    Invernizzi, R
    Zhivotovsky, B
    Fadeel, B
    Forsblom, AM
    Travaglino, E
    Samuelsson, J
    Hast, R
    Nilsson, L
    Wibom, R
    Grandien, A
    Cazzola, M
    Hellstrom-Lindberg, E
    BLOOD, 2004, 104 (11) : 138A - 138A
  • [8] CHROMOSOMAL STUDIES IN 24 PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIAS (AML) AND MYELODYSPLASTIC SYNDROMES (MDS)
    WEH, HJ
    HOFFMANN, R
    SUCIU, S
    KUSE, R
    HOSSFELD, DK
    BLUT, 1987, 55 (04): : 236 - 236
  • [9] CD34 positive progenitors can be cytogenetically normal in patients with myelodysplastic syndromes (MDS).
    Abruzzese, E
    Radford, JE
    Pettenati, MJ
    Rao, PN
    Hurd, DD
    Rainer, RO
    Powell, BL
    Torti, FM
    BLOOD, 1996, 88 (10) : 1906 - 1906
  • [10] Hypomethylation therapy of decitabine in patients with myelodysplastic syndromes (MDS) induces apoptosis and reduces proliferation.
    Jilani, I
    Kantarjian, H
    Gorre, M
    Issa, JP
    Bennett, J
    Raza, A
    Ravandi, F
    Saba, H
    Albitar, M
    BLOOD, 2005, 106 (11) : 112A - 112A
12345